Helicobacter Pylori Diagnostics Market Expected to Reach $926.8 Million by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Helicobacter Pylori Diagnostics Market," The helicobacter pylori diagnostics market size was valued at $552.65 million in 2022, and is estimated to reach $926.8 million by 2032, growing at a CAGR of 5.3% from 2023 to 2032.

Helicobacter pylori diagnostics refers to the diagnostic tests that are performed to detect the presence of the bacteria Helicobacter pylori in a patient's stomach or digestive system. H. pylori testing is often recommended for patients with symptoms of digestive problems, such as stomach pain, nausea, vomiting, and indigestion. It is recommended for patients with a history of peptic ulcers, gastric cancer, or other digestive problems. 

Helicobacter pylori diagnostics market trends that drive the growth of market include increase in awareness about the importance of early diagnosis of H. pylori infection and surge in demand for minimally invasive methods for H. pylori testing. In addition, advancements in Helicobacter pylori diagnostics have led to the development of more accurate and reliable tools, which have further increased the demand for H. pylori testing devices. For instance, the development of molecular diagnostic tests such as polymerase chain reaction (PCR) have improved accuracy and sensitivity of non-invasive tests for H. pylori infection. These tests can detect H. pylori DNA or RNA in stool samples, which is a highly specific and sensitive indicator of infection. Such advancements in H. pylori testing drive the market growth. 

In addition, H. pylori infection is a major cause of various gastrointestinal diseases such as gastritis, peptic ulcers, and gastric cancer. Thus, the rise in incidence of these diseases drives the demand for H. pylori diagnostic tests and propels helicobacter pylori diagnostics market size. Furthermore, point-of-care testing (POCT) has become increasingly popular due to its convenience, speed, and accuracy, which is expected to drive market growth. It provides rapid and accurate diagnostic results that fosters the demand for POCT-based diagnostic tests. For instance, H. pylori urea breath test (UBT) is a POCT-based diagnostic test that detects the presence of H. pylori bacteria in the stomach. This test is highly accurate and provides diagnostic results within a few minutes, making it ideal for use in point-of-care settings.  

Depending on test type, the market is divided into non-invasive test and invasive test. Non-invasive test segment is further segmented into the serology test, stool antigen test, and carbon urea breath test. The non-invasive segment accounted for the largest helicobacter pylori diagnostics market share in 2022 and is expected to register the highest CAGR during the forecast period. This is attributed to high adoption of non-invasive tests such as serology and stool antigen tests   as they are easy to perform, requiring only a blood or stool sample, and can be done without the need for specialized equipment or trained personnel. 

Depending on the method, the market is classified into laboratory-based tests and point of care (POC) test. The laboratory-based test segment had the largest share in 2022. This is attributed to high adoption of laboratory-based tests as they provide high sensitivity and specificity of immunoassays, which makes them an ideal choice for diagnosing diseases. However, the point of care (POC) test segment is expected to register the highest CAGR during the forecast period. 

This is attributed to the surge in demand for point of care testing as they are convenient in performing the tests and have faster turnaround time for results. In addition, point-of-care tests can provide immediate results, which allows faster diagnosis and treatment of conditions such as H. pylori infection that drives the market growth.  Depending on the end user, the market is categorized into hospitals, diagnostic laboratories, and others. The diagnostic laboratories segment dominated the market in 2022 and is expected to remain dominant during the forecast period owing to availability of trained medical staff in labs that helps to provide better services to patients and increase in patient admission in laboratories for H. pylori testing.

However, the others segment is expected to register the highest CAGR during the helicobacter pylori diagnostics market analysis. This is attributed to increase in demand for non-invasive and user-friendly diagnostic tests, the growing trend toward self-diagnosis and self-treatment, and the availability of advanced technologies that allow for accurate and reliable H. pylori testing at home.

Region wise, North America was the largest Helicobacter pylori diagnostics market share contributor in the in 2022, owing to easy availability of products for diagnosis of H. pylori bacteria, advanced healthcare infrastructure, and rise in adoption of non-invasive methods. In addition, higher health awareness and surge in adoption of advanced tools for H. pylori testing drive the market growth in this region. 

Key players operating in the region have adopted product approval, acquisition, and agreement as their key strategies to expand their product portfolio. For instance, in July 2021, Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced that it signed a definitive agreement to acquire the North American BreathTek business from Otsuka America Pharmaceutical, Inc. Such strategies adopted by the key players support the market growth in this region. 

However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period owing to increase in health awareness and growth in healthcare infrastructure. In addition, the increase in prevalence of infectious diseases such as gastric cancer in the region, along with the growing awareness about the early diagnosis, drives the growth during Helicobacter pylori diagnostics market forecast. 
 
Key findings of the study 
• By test type, non-invasive segment was highest contributor to the helicobacter pylori diagnostics industry in 2022. 
• By method, the laboratory-based test segment dominated the market in 2022.   
• By end user, the diagnostic laboratories segment dominated the helicobacter pylori diagnostics industry in 2022.
• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.